What are the treatment options for ulcerative proctitis?

Treatment Options for Ulcerative Proctitis

For mild to moderate ulcerative proctitis, start with rectal 5-ASA suppositories at 1 g daily as first-line therapy to induce remission, and continue the same therapy for maintenance. This represents the strongest evidence-based recommendation with high-quality data supporting both induction and maintenance of remission 1.

First-Line Therapy: Topical 5-ASA

The Toronto Consensus Guidelines provide the clearest treatment algorithm for ulcerative proctitis:

• Rectal 5-ASA at 1 g daily is superior to placebo with impressive efficacy (pooled OR 8.30 for symptomatic remission and 5.31 for endoscopic remission) 1
• Suppositories are preferred over enemas for proctitis because their distribution better matches the limited disease extent 1
• No dose-response benefit exists for doses exceeding 1 g daily in proctitis 1
• Once-daily dosing is recommended over multiple daily doses for better adherence 1

Recent meta-analyses confirm this approach, showing topical 5-ASA achieves clinical remission with RR 2.72 (95% CI 1.94-3.82) for induction and RR 2.09 (95% CI 1.26-3.46) for maintenance 2.

Second-Line Options When 5-ASA Fails

If patients fail to respond to rectal 5-ASA within 4-8 weeks, escalate to rectal corticosteroids 1. The evidence shows:

• Topical corticosteroids are superior to placebo (RR 2.83,95% CI 1.62-4.92) 2
• Topical budesonide specifically shows efficacy (RR 2.34,95% CI 1.44-3.81) 2
• Combination therapy with topical 5-ASA plus topical corticosteroids is more effective than either agent alone (100% response vs 70% for beclomethasone alone vs 76% for 5-ASA alone) 3

Importantly, rectal 5-ASA is actually superior to rectal corticosteroids for inducing symptomatic remission (pooled OR 1.65,95% CI 1.11-2.45) 1, which reinforces starting with 5-ASA first.

Oral Therapy Considerations

While topical therapy is preferred, oral 5-ASA can be added:

• Oral 5-ASA at 2.0-4.8 g/day can be used as alternative first-line therapy 1
• Combination of rectal and oral 5-ASA may be superior to oral alone, though this is a weak recommendation 1
• Meta-analyses show rectal 5-ASA is not definitively superior to oral 5-ASA (pooled OR 2.25,95% CI 0.53-9.54), but the topical route makes more physiologic sense for distal disease 1

Refractory Proctitis: Advanced Therapies

For true refractory disease (defined as failure to achieve corticosteroid-free remission despite optimal 5-ASA and corticosteroid therapy 1):

Topical Tacrolimus

• Shows superiority over placebo for induction 2
• Limited but positive evidence for refractory cases 4

Small Molecules

• Etrasimod demonstrates strong efficacy: RR 4.71 (95% CI 1.2-18.49) for induction and RR 2.08 (95% CI 1.31-3.32) for maintenance 2
• This represents the most robust data for advanced therapy specifically in proctitis

Biologics

• Anti-TNF therapy is recommended when patients fail thiopurines or corticosteroids 1
• However, evidence specific to isolated proctitis is extremely limited 3, 4
• A 2025 survey revealed 49% of physicians are more reluctant to start advanced therapy in isolated proctitis compared to more extensive disease 5
• When used, anti-TNF is the preferred first-line advanced therapy (48.4% of practitioners) 5

Immunomodulators

• Azathioprine may be effective for maintenance in corticosteroid-dependent patients 1, 4
• Not recommended for induction (strong recommendation against) 1

Critical Pitfalls to Avoid

1. Don't assume treatment failure prematurely: Evaluate response at 4-8 weeks for 5-ASA 1 and within 2 weeks for corticosteroids 1

2. Before escalating therapy, exclude:

   • Non-compliance with topical therapy
   • Proximal disease extension (repeat endoscopy)
   • Superimposed C. difficile infection 6

3. Never use oral corticosteroids for maintenance: They are ineffective and cause significant adverse effects 1

4. Don't switch between oral 5-ASA formulations: Strong recommendation against this practice if one formulation fails 1

Maintenance Strategy

Once remission is achieved, continue the same therapy that induced remission 1:

• If rectal 5-ASA induced remission, continue rectal 5-ASA for maintenance (strong recommendation, moderate-quality evidence)
• If oral 5-ASA was used, continue at least 2 g/day for maintenance

Monitoring and Treatment Targets

Recent 2025 data emphasizes the importance of endoscopic healing (Mayo endoscopic score 0-1) in proctitis 7:

• Patients achieving endoscopic healing had fewer ED visits (8.3% vs 21%), hospitalizations (5.5% vs 18%), and longer time to relapse (21 vs 9 months)
• This challenges the older notion that mucosal healing is less important in proctitis 1

Perform endoscopic assessment at 3-6 months (34.2% of practitioners) or 6-12 months (48.4%) after treatment initiation 5. Use fecal calprotectin (75.9% of practitioners) and CRP (67.1%) for non-invasive monitoring 5.

The 2022 IOIBD PROCTRIAL consensus recommends primary endpoints should include both patient-reported outcomes (rectal bleeding subscore 0, stool frequency decrease) and endoscopic improvement (Mayo endoscopic subscore 0-1) 8.